West Pharmaceutical Services, Inc. (WST) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $412.00 (-1.07%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 13, 2026 | Dan Leonard | UBS | $340.00 | -17.5% |
| Feb 13, 2026 | Luke Sergott | Barclays | $265.00 | -35.7% |
| Feb 10, 2026 | David Windley | Jefferies | $295.00 | -28.4% |
| Feb 3, 2026 | Daniel Markowitz | Evercore ISI | $320.00 | -22.3% |
| Oct 24, 2025 | Dan Leonard | UBS | $355.00 | -13.8% |
| Oct 24, 2025 | Justin Bowers | Deutsche Bank | $345.00 | -16.3% |
| Oct 23, 2025 | Daniel Markowitz | Evercore ISI | $390.00 | -5.3% |
| Sep 15, 2025 | Jamie Clark | Redburn Partners | $311.00 | -24.5% |
| Jun 24, 2025 | Luke Sergott | Barclays | $245.00 | -40.5% |
| Nov 19, 2024 | David Windley | Jefferies | $393.00 | -4.6% |
| Feb 7, 2024 | David Windley | Jefferies | $536.00 | +30.1% |
Top Analysts Covering WST
WST vs Sector & Market
| Metric | WST | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.14 | 2.25 | 2.41 |
| Analyst Count | 14 | 8 | 19 |
| Target Upside | +1.8% | +153002.0% | +21.5% |
| P/E Ratio | 55.01 | 3.42 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.28B | $3.29B | $3.30B | 11 |
| 2027-03-31 | $824M | $830M | $838M | 1 |
| 2027-06-30 | $856M | $862M | $871M | 1 |
| 2027-09-30 | $869M | $875M | $883M | 1 |
| 2027-12-31 | $877M | $884M | $892M | 1 |
| 2028-03-31 | $891M | $898M | $907M | 1 |
| 2028-06-30 | $901M | $907M | $916M | 1 |
| 2028-09-30 | $916M | $923M | $931M | 1 |
| 2028-12-31 | $934M | $941M | $950M | 1 |
| 2029-12-31 | $3.92B | $3.97B | $4.03B | 3 |
| 2030-12-31 | $4.06B | $4.11B | $4.17B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.75 | $8.29 | $8.47 | 8 |
| 2027-03-31 | $1.98 | $2.00 | $2.03 | 1 |
| 2027-06-30 | $2.22 | $2.24 | $2.27 | 1 |
| 2027-09-30 | $2.35 | $2.38 | $2.41 | 1 |
| 2027-12-31 | $2.49 | $2.51 | $2.54 | 1 |
| 2028-03-31 | $2.47 | $2.49 | $2.52 | 1 |
| 2028-06-30 | $2.61 | $2.63 | $2.67 | 1 |
| 2028-09-30 | $2.63 | $2.66 | $2.69 | 1 |
| 2028-12-31 | $2.86 | $2.89 | $2.92 | 1 |
| 2029-12-31 | $11.41 | $11.60 | $11.82 | 1 |
| 2030-12-31 | $12.23 | $12.44 | $12.68 | 1 |
Frequently Asked Questions
What is the analyst consensus for WST?
The consensus among 14 analysts covering West Pharmaceutical Services, Inc. (WST) is Buy with an average price target of $407.00.
What is the highest price target for WST?
The highest price target for WST is $536.00, set by David Windley at Jefferies on 2024-02-07.
What is the lowest price target for WST?
The lowest price target for WST is $245.00, set by Luke Sergott at Barclays on 2025-06-24.
How many analysts cover WST?
14 analysts have issued ratings for West Pharmaceutical Services, Inc. in the past 12 months.
Is WST a buy or sell right now?
Based on 14 analyst ratings, WST has a consensus rating of Buy (2.14/5) with a +1.8% upside to the consensus target of $407.00.
What are the earnings estimates for WST?
Analysts estimate WST will report EPS of $8.29 for the period ending 2026-12-31, with revenue estimated at $3.29B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.